Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Business & Industry
- CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
- Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
- BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
- Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
- AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
Research & Development
- 'Biohybrid' device could restore function in paralysed limbs
- Scientists use tardigrade proteins for human health breakthrough
- DNA treatment could delay paralysis that strikes nearly all patients with ALS
- Scientists reveal a potential new approach to treating liver cancer
- Normalizing tumor blood vessels may improve immunotherapy against brain cancer
- Engineered bacteria find tumors, then alert the authorities
- First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA grants Accelerated Approval for Alzheimer's disease treatment
- FDA approves new HIV drug for adults with limited treatment options
- FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease